US20040102486A1
(en)
*
|
1998-11-12 |
2004-05-27 |
Smithkline Beecham Corporation |
Novel method of treatment
|
US20030153607A1
(en)
*
|
1998-11-12 |
2003-08-14 |
Smithkline Beecham P.L.C. |
Novel composition and use
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
ES2374717T3
(es)
|
1999-10-29 |
2012-02-21 |
Euro-Celtique S.A. |
Formulaciones de hidrocodona de liberación controlada.
|
EP1175205B1
(en)
*
|
1999-11-12 |
2006-06-14 |
Abbott Laboratories |
Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
|
JP2004512354A
(ja)
|
2000-10-30 |
2004-04-22 |
ユーロ−セルティーク,エス.エイ. |
ヒドロコドン放出制御製剤
|
CA2359812C
(en)
*
|
2000-11-20 |
2004-02-10 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
|
BE1015608A6
(fr)
*
|
2003-07-15 |
2005-06-07 |
Messadek Jallal |
Traitement des arterites.
|
US8323692B2
(en)
|
2002-02-21 |
2012-12-04 |
Valeant International Bermuda |
Controlled release dosage forms
|
EP1476139B1
(en)
*
|
2002-02-21 |
2017-05-17 |
Valeant Pharmaceuticals Luxembourg S.à.r.l. |
Controlled release dosage forms
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
KR100897890B1
(ko)
|
2002-06-17 |
2009-05-18 |
인벤티아 헬스케어 피브이티. 엘티디. |
티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
|
US7704527B2
(en)
*
|
2002-10-25 |
2010-04-27 |
Collegium Pharmaceutical, Inc. |
Modified release compositions of milnacipran
|
DE10307728B4
(de)
*
|
2003-02-24 |
2005-09-22 |
Clariant Gmbh |
Korrosions-und Gashydratinhibitoren mit verbesserter Wasserlöslichkeit und erhöhter biologischer Abbaubarkeit und derartige Verbindungen
|
WO2004091601A1
(fr)
*
|
2003-04-17 |
2004-10-28 |
Jallal Messadek |
Formulations orales flottantes pour la liberation controlee de la betaine
|
PT2316456T
(pt)
|
2003-04-29 |
2017-09-05 |
Orexigen Therapeutics Inc |
Composições para afetar a perda de peso compreendendo naltrexona e bupropion
|
US20050025825A1
(en)
|
2003-07-31 |
2005-02-03 |
Xanodyne Pharmacal, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
US20090214644A1
(en)
*
|
2003-07-31 |
2009-08-27 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
US8377952B2
(en)
*
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
WO2005065639A2
(en)
*
|
2003-11-21 |
2005-07-21 |
Torrent Pharmaceuticals Limited |
Novel pharmaceutical compositions
|
CZ300438B6
(cs)
*
|
2003-11-25 |
2009-05-20 |
Pliva Hrvatska D.O.O. |
Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu
|
EP1841414A1
(en)
*
|
2003-12-31 |
2007-10-10 |
Alpharma, Inc. |
Rosiglitazone and metformin formulations
|
US8022106B2
(en)
*
|
2004-03-04 |
2011-09-20 |
Ferring B.V. |
Tranexamic acid formulations
|
US20050245614A1
(en)
*
|
2004-03-04 |
2005-11-03 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations
|
US20090215898A1
(en)
*
|
2004-03-04 |
2009-08-27 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations
|
US7947739B2
(en)
|
2004-03-04 |
2011-05-24 |
Ferring B.V. |
Tranexamic acid formulations
|
US20050244495A1
(en)
|
2004-03-04 |
2005-11-03 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations
|
US20060185357A1
(en)
*
|
2004-05-07 |
2006-08-24 |
Kovacevich Ian D |
Independently drawing and tensioning lines with bi-directional rotary device having two spools
|
WO2005123134A2
(en)
*
|
2004-05-14 |
2005-12-29 |
Cadila Healthcare Limited |
A controlled release delivery system for metformin
|
DE602005025755D1
(de)
|
2004-06-04 |
2011-02-17 |
Teva Pharma |
Irbesartan enthaltende pharmazeutische zusammensetzung
|
BE1016128A6
(fr)
*
|
2004-07-22 |
2006-03-07 |
Messadek Jallal |
Combinaisons therapeutiques
|
US7700608B2
(en)
|
2004-08-04 |
2010-04-20 |
Shire Holdings Ag |
Quinazoline derivatives and their use in the treatment of thrombocythemia
|
PE20060652A1
(es)
*
|
2004-08-27 |
2006-08-11 |
Novartis Ag |
Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusion
|
CZ296459B6
(cs)
*
|
2004-09-14 |
2006-03-15 |
Pliva-Lachema A. S. |
Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
|
WO2006031024A1
(en)
|
2004-09-15 |
2006-03-23 |
Gl Pharmtech Corp. |
A sustained-release tablet containing doxazosin mesylate
|
WO2006050581A2
(en)
*
|
2004-11-10 |
2006-05-18 |
Jallal Messadek |
Betaine as agent against arthropod - or mosquito -borne diseases
|
US7619007B2
(en)
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
GB0502479D0
(en)
*
|
2005-02-07 |
2005-03-16 |
Sb Pharmco Inc |
Novel compositions
|
EP2242489A1
(en)
*
|
2005-02-15 |
2010-10-27 |
Jallal Messadek |
Combination therapeutic compositions and method of use
|
US20060222709A1
(en)
*
|
2005-03-18 |
2006-10-05 |
Agi Therapeutics Research Ltd. |
Metformin methods and formulations for treating chronic constipation
|
CA2604052C
(en)
*
|
2005-04-06 |
2014-07-08 |
Adamas Pharmaceuticals, Inc. |
Methods and compositions for the treatment of cns-related conditions
|
US7348027B2
(en)
*
|
2005-04-08 |
2008-03-25 |
Bayer Healthcare Llc |
Taste masked veterinary formulation
|
US20060229261A1
(en)
*
|
2005-04-12 |
2006-10-12 |
John Devane |
Acarbose methods and formulations for treating chronic constipation
|
US20100087546A1
(en)
*
|
2005-04-20 |
2010-04-08 |
Biogenic Innovations, Llc |
Use of dimethyl sulfone (msm) to reduce homocysteine levels
|
CA2606740A1
(en)
*
|
2005-05-03 |
2006-11-09 |
Mutual Pharmaceutical Company, Inc. |
Quinine-containing controlled-release formulations
|
US8088773B2
(en)
|
2005-05-12 |
2012-01-03 |
The Texas A&M University System |
Therapeutic compositions and methods
|
US20070287740A1
(en)
*
|
2005-05-25 |
2007-12-13 |
Transcept Pharmaceuticals, Inc. |
Compositions and methods of treating middle-of-the night insomnia
|
US8242131B2
(en)
*
|
2005-05-25 |
2012-08-14 |
Transcept Pharmaceuticals, Inc. |
Methods of treating middle-of-the-night insomnia
|
US20070225322A1
(en)
*
|
2005-05-25 |
2007-09-27 |
Transoral Pharmaceuticals, Inc. |
Compositions and methods for treating middle-of-the night insomnia
|
US7544373B2
(en)
|
2007-04-02 |
2009-06-09 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US7919483B2
(en)
|
2005-06-24 |
2011-04-05 |
Medicis Pharmaceutical Corporation |
Method for the treatment of acne
|
US8252776B2
(en)
|
2007-04-02 |
2012-08-28 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US7541347B2
(en)
|
2007-04-02 |
2009-06-02 |
Medicis Pharmaceutical Coropration |
Minocycline oral dosage forms for the treatment of acne
|
US9192615B2
(en)
|
2008-08-06 |
2015-11-24 |
Medicis Pharmaceutical Corporation |
Method for the treatment of acne and certain dosage forms thereof
|
KR101452518B1
(ko)
|
2005-08-22 |
2014-10-21 |
멜리어 파마슈티칼스 아이, 인코포레이티드 |
Lyn 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제
|
RU2385712C2
(ru)
*
|
2005-08-24 |
2010-04-10 |
Рубикон Рисёч Пвт Лтд. |
Рецептура с контролируемым высвобождением
|
US8480797B2
(en)
*
|
2005-09-12 |
2013-07-09 |
Abela Pharmaceuticals, Inc. |
Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
|
WO2007033083A2
(en)
*
|
2005-09-12 |
2007-03-22 |
Abela Pharmaceuticals, Inc. |
Systems for removing dimethyl sulfoxide (dmso) or related compounds, or odors associated with same
|
EP1937286B1
(en)
|
2005-09-12 |
2016-03-09 |
Abela Pharmaceuticals, Inc. |
Compositions comprising dimethyl sulfoxide (dmso)
|
WO2007033180A1
(en)
|
2005-09-12 |
2007-03-22 |
Abela Pharmaceuticals, Inc. |
Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
|
DE102005054610B4
(de)
*
|
2005-11-08 |
2010-06-10 |
Awd.Pharma Gmbh & Co. Kg |
Flupirtin enthaltende Arzneimittelzubereitung mit kontrollierter Wirkstofffreisetzung
|
CA2624361A1
(en)
*
|
2005-11-21 |
2007-05-31 |
The Board Of Trustees Of The University Of Alabama For And On Behalf Of The University Of Alabama |
Methods of using small molecule compounds for neuroprotection
|
JP5180092B2
(ja)
|
2005-11-22 |
2013-04-10 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
インスリン感受性を増すための組成物および方法
|
DK1954241T3
(da)
*
|
2005-11-28 |
2012-06-18 |
Orexigen Therapeutics Inc |
Zonisamid-formulering med vedvarende frigivelse
|
FR2896157B1
(fr)
*
|
2006-01-13 |
2008-09-12 |
Merck Sante Soc Par Actions Si |
Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
|
US7427414B2
(en)
*
|
2006-01-18 |
2008-09-23 |
Astron Research Limited |
Modified release oral dosage form using co-polymer of polyvinyl acetate
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
US20080069891A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
US7811549B2
(en)
|
2006-07-05 |
2010-10-12 |
Adenobio N.V. |
Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
|
US20090238763A1
(en)
|
2006-07-09 |
2009-09-24 |
Chongxi Yu |
High penetration compositions and uses thereof
|
US20090221703A1
(en)
|
2006-07-09 |
2009-09-03 |
Chongxi Yu |
High penetration composition and uses thereof
|
RU2009104001A
(ru)
*
|
2006-07-11 |
2010-08-20 |
Мьючуал Фармасьютикал Компани, Инк. (Us) |
Композиции с контролируемым высвобождением
|
US8765178B2
(en)
*
|
2006-07-19 |
2014-07-01 |
Watson Laboratories, Inc. |
Controlled release formulations and associated methods
|
CN101500983B
(zh)
*
|
2006-07-26 |
2015-09-16 |
于崇曦 |
具有快速皮肤穿透速度的带正电荷的水溶性二氟尼柳及相关化合物的前药
|
CN105439877B
(zh)
*
|
2006-07-26 |
2019-07-23 |
于崇曦 |
带正电荷的水溶性二氟尼柳及相关化合物的前药
|
MY149863A
(en)
|
2006-08-03 |
2013-10-31 |
Nitec Pharma Ag |
Delayed-release glucocorticoid treatment of rheumatoid disease
|
EP2051696A2
(en)
*
|
2006-08-18 |
2009-04-29 |
Morton Grove Pharmaceuticals, Inc. |
Stable liquid levetiracetam compositions and methods
|
BRPI0715872A2
(pt)
*
|
2006-08-23 |
2014-08-26 |
Wyeth Corp |
Composto; composição farmacêutica; método de preparação do composto; composto preparado pelo método; e método de tratamento de um transtorno em um mamífero necessitado
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
US20080051375A1
(en)
*
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
|
WO2008027557A2
(en)
*
|
2006-08-31 |
2008-03-06 |
Spherics, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
US20110165236A1
(en)
*
|
2006-09-22 |
2011-07-07 |
Biokey, Inc. |
Controlled release hydrogel formulation
|
US20080075785A1
(en)
*
|
2006-09-22 |
2008-03-27 |
San-Laung Chow |
Controlled release hydrogel formulation
|
CN101588795A
(zh)
|
2006-11-09 |
2009-11-25 |
奥雷西根治疗公司 |
包含中间快速溶解层的分层药物制剂
|
AU2007319472B2
(en)
|
2006-11-09 |
2013-01-17 |
Nalpropion Pharmaceuticals Llc |
Methods Of Administering Weight Loss Medications
|
JP5489719B2
(ja)
|
2006-11-17 |
2014-05-14 |
スパーナス ファーマシューティカルズ インコーポレイテッド |
トピラマートの徐放性配合物
|
KR100822180B1
(ko)
*
|
2006-11-22 |
2008-04-16 |
광동제약 주식회사 |
마진돌 함유 정제의 안정화 방법
|
WO2008066845A2
(en)
*
|
2006-11-28 |
2008-06-05 |
Ampla Pharmaceuticals Inc. |
Treatment of metabolic syndrome with norfluoxetine
|
US20080132535A1
(en)
*
|
2006-11-30 |
2008-06-05 |
Transcept Pharmaceuticals, Inc. |
Stabilized Zolpidem Pharmaceutical Compositions
|
MX2009003911A
(es)
*
|
2006-12-04 |
2009-05-28 |
Supernus Pharmaceuticals Inc |
Formulaciones de liberacion inmediata, mejoradas de topiramato.
|
ES2395120T3
(es)
*
|
2006-12-20 |
2013-02-08 |
Cardoz Ab |
Combinación de pemirolast y ramotrobán para su uso en el tratamiento de transtornos inflamatorios
|
WO2008087371A1
(en)
*
|
2007-01-16 |
2008-07-24 |
Cardoz Ab |
New combination for use in the treatment of inflammatory disorders
|
WO2008103818A1
(en)
*
|
2007-02-21 |
2008-08-28 |
University Of Louisville Research Foundation |
Therapeutic cotinine compositions
|
EP1967182A1
(en)
*
|
2007-03-07 |
2008-09-10 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Pharmaceutical composition comprising a salt of rosigliatazone
|
KR20090119960A
(ko)
*
|
2007-03-15 |
2009-11-23 |
토요 보세키 가부시기가이샤 |
구강 점막 첩부 부프레노르핀 제제의 제조 방법
|
US20100143471A1
(en)
*
|
2007-03-21 |
2010-06-10 |
Lupin Limited |
Novel reduced dose pharmaceutical compositions of fexofenadine and pseudoephedrine
|
KR100782310B1
(ko)
|
2007-03-22 |
2007-12-06 |
현대약품 주식회사 |
갈란타민 또는 이의 약학적으로 허용 가능한 염을 포함하는약학 조성물
|
WO2008121107A1
(en)
*
|
2007-04-02 |
2008-10-09 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US20160331729A9
(en)
|
2007-04-11 |
2016-11-17 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
US11241420B2
(en)
|
2007-04-11 |
2022-02-08 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
CN110403942A
(zh)
*
|
2007-04-11 |
2019-11-05 |
奥默罗斯公司 |
预防和治疗成瘾的组合物和方法
|
WO2008150845A1
(en)
*
|
2007-05-31 |
2008-12-11 |
Vanderbilt University |
Screening for wnt pathway modulators and pyrvinium for the treatment of cance
|
KR20190091378A
(ko)
*
|
2007-06-04 |
2019-08-05 |
테크필즈 인크 |
매우 높은 피부 및 막 침투율을 가지는 비스테로이드성 소염제(nsaia) 약물전구체 및 이들의 새로운 의약적 용도
|
US20090004231A1
(en)
|
2007-06-30 |
2009-01-01 |
Popp Shane M |
Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring
|
US8404275B2
(en)
|
2007-07-01 |
2013-03-26 |
Vitalis Llc |
Combination tablet with chewable outer layer
|
WO2009007680A2
(en)
|
2007-07-11 |
2009-01-15 |
Cardoz Ab |
Combinations comprising a mast cell inhibitor and a statin for use in the treatment of inflammatory disorders
|
US20090124587A1
(en)
*
|
2007-07-12 |
2009-05-14 |
Auerbach Alan H |
METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
|
US8067632B2
(en)
*
|
2007-07-26 |
2011-11-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Process to produce prostratin and structural or functional analogs thereof
|
US20090035370A1
(en)
*
|
2007-08-02 |
2009-02-05 |
Drugtech Corporation |
Dosage form and method of use
|
US8871275B2
(en)
|
2007-08-08 |
2014-10-28 |
Inventia Healthcare Private Limited |
Extended release compositions comprising tolterodine
|
US8802156B2
(en)
|
2007-11-14 |
2014-08-12 |
Laboratorios Farmacéuticos Rovi, S.A. |
Pharmaceutical forms for the release of active compounds
|
WO2009065193A1
(en)
*
|
2007-11-21 |
2009-05-28 |
Jallal Messadek |
Treatment of aspirin resistance with betaine and/or betaine enriched molasses
|
US20090185973A1
(en)
*
|
2008-01-22 |
2009-07-23 |
Adenobio N.V. |
Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
|
AU2009219250A1
(en)
*
|
2008-02-28 |
2009-09-03 |
Novartis Ag |
Valsartan solid oral dosage forms and methods of making such formulations
|
WO2009114520A2
(en)
*
|
2008-03-10 |
2009-09-17 |
Pharmain Corporation |
Compositions for treatment with metallopeptidases, methods of making and using the same
|
CN101550162B
(zh)
*
|
2008-04-03 |
2015-11-25 |
北京华昊中天生物技术有限公司 |
福司曲星衍生物及其药用用途
|
ES2395002T3
(es)
*
|
2008-04-07 |
2013-02-07 |
Cardoz Ab |
Nueva combinación para uso en el tratamiento de trastornos inflamatorios
|
SI2276473T1
(sl)
|
2008-04-18 |
2017-02-28 |
Intec Pharma Ltd. |
Gastro retencijsko dajanje zdravila karbidope/levodope
|
KR101749032B1
(ko)
|
2008-05-28 |
2017-06-20 |
레베라겐 바이오파마 인코포레이티드 |
질환의 치료를 위한 NF-κB 의 비호르몬성 스테로이드 조절제
|
MX2010012909A
(es)
|
2008-05-30 |
2011-02-25 |
Orexigen Therapeutics Inc |
Metodos para tratamiento de condiciones de grasa visceral.
|
TR201009949T1
(tr)
*
|
2008-06-02 |
2011-03-21 |
Dr. Reddy's Laboratories, Ltd. |
Salımı değiştirilmiş niasin formülasyonları.
|
US20100178341A1
(en)
*
|
2008-06-11 |
2010-07-15 |
Ranbaxy Laboratories Limited |
BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR
|
US8552184B2
(en)
*
|
2008-07-03 |
2013-10-08 |
Melior Pharmaceuticals I, Inc. |
Compounds and methods for treating disorders related to glucose metabolism
|
CA2960254A1
(en)
|
2008-08-01 |
2010-02-04 |
Arca Biopharma, Inc. |
Methods and compositions involving (s)-bucindolol
|
US20100055183A1
(en)
*
|
2008-08-28 |
2010-03-04 |
Osteogenex Inc. |
Trimeprazine and ethopropazine derivatives for promoting bone growth
|
EP2361092A4
(en)
*
|
2008-09-04 |
2012-07-11 |
Anthony I Rozmanith |
MEDICAL CARE
|
US20100068233A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Modifiable dosage form
|
US20100068283A1
(en)
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Ex VIVO modifiable particle or polymeric material medicament carrier
|
US20100068254A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Mahalaxmi Gita Bangera |
Modifying a medicament availability state of a final dosage form
|
US20100069887A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Multiple chamber ex vivo adjustable-release final dosage form
|
US20100069821A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Ex vivo modifiable medicament release-sites final dosage form
|
US20100068235A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete LLC, a limited liability corporation of Deleware |
Individualizable dosage form
|
US20100068275A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Personalizable dosage form
|
US8198268B2
(en)
*
|
2008-10-31 |
2012-06-12 |
Janssen Biotech, Inc. |
Tianeptine sulfate salt forms and methods of making and using the same
|
BRPI0921494A2
(pt)
|
2008-11-03 |
2018-10-30 |
Prad Reasearch And Development Ltd |
método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
|
US8771735B2
(en)
*
|
2008-11-04 |
2014-07-08 |
Jazz Pharmaceuticals, Inc. |
Immediate release dosage forms of sodium oxybate
|
US8778398B2
(en)
|
2008-11-04 |
2014-07-15 |
Jazz Pharmaceuticals, Inc. |
Immediate release formulations and dosage forms of gamma-hydroxybutyrate
|
KR20210123406A
(ko)
|
2008-12-04 |
2021-10-13 |
충시 위 |
고투과력을 가진 조성물 및 이의 적용
|
WO2010064100A1
(en)
*
|
2008-12-04 |
2010-06-10 |
Intec Pharma Ltd. |
Baclofen gastroretentive drug delivery system
|
WO2010083360A2
(en)
*
|
2009-01-16 |
2010-07-22 |
Mutual Pharmaceutical Company, Inc. |
Controlled-release formulations
|
AU2010207740B2
(en)
*
|
2009-01-26 |
2016-06-16 |
Nitec Pharma Ag |
Delayed-release glucocorticoid treatment of asthma
|
NZ582836A
(en)
*
|
2009-01-30 |
2011-06-30 |
Nitec Pharma Ag |
Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
|
AU2010213678B2
(en)
*
|
2009-02-13 |
2015-11-26 |
Romark Laboratories L.C. |
Controlled release pharmaceutical formulations of nitazoxanide
|
US20100280117A1
(en)
*
|
2009-04-30 |
2010-11-04 |
Xanodyne Pharmaceuticals, Inc. |
Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
|
WO2010134938A1
(en)
*
|
2009-05-18 |
2010-11-25 |
Dr. Reddy's Laboratories Ltd. |
Modified release niacin pharmaceutical formulations
|
CN102438587B
(zh)
|
2009-05-19 |
2015-08-19 |
神经层有限公司 |
用于多巴脱羧酶抑制剂连续施用的组合物
|
SG10201402863PA
(en)
*
|
2009-06-05 |
2014-10-30 |
Tau Therapeutics Llc |
Interlaced method for treating cancer or a precancerous condition
|
US9855212B2
(en)
|
2009-10-30 |
2018-01-02 |
Abela Pharmaceuticals, Inc. |
Dimethyl sulfoxide (DMSO) or DMSO and methylsulfonylmethane (MSM) formulations to treat infectious diseases
|
RU2607526C2
(ru)
|
2009-11-23 |
2017-01-10 |
Кьюбист Фармасьютикалз ЭлЭлСи |
Липопептидные композиции и родственные способы
|
MX365650B
(es)
|
2009-12-02 |
2019-06-10 |
Adamas Pharmaceuticals Inc |
Composiciones de amantadina y metodos para su uso.
|
NL1037569C2
(en)
*
|
2009-12-18 |
2011-06-21 |
Eurovet Animal Health B V |
Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use.
|
US20110150986A1
(en)
*
|
2009-12-18 |
2011-06-23 |
Kristin Arnold |
Quinine formulations, method of making, and metho of use thereof
|
WO2011074660A1
(ja)
*
|
2009-12-18 |
2011-06-23 |
田辺三菱製薬株式会社 |
溶出安定性製剤
|
EP3659604A1
(en)
|
2010-01-11 |
2020-06-03 |
Nalpropion Pharmaceuticals, Inc. |
Methods of providing weight loss therapy in patients with major depression
|
USD661900S1
(en)
|
2010-02-22 |
2012-06-19 |
Bajer Design & Marketing, Inc. |
Collapsible structure
|
WO2011109262A2
(en)
|
2010-03-01 |
2011-09-09 |
Tau Therapeutics Llc |
Cancer diagnosis and imaging
|
SG10201504529WA
(en)
*
|
2010-03-09 |
2015-07-30 |
Alkermes Pharma Ireland Ltd |
Alcohol Resistant Enteric Pharmaceutical Compositions
|
MX2020011961A
(es)
|
2010-03-24 |
2022-04-19 |
Jazz Pharmaceuticals Inc |
Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
|
WO2011127048A2
(en)
|
2010-04-05 |
2011-10-13 |
Validus Biopharma |
NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
|
WO2011143120A1
(en)
|
2010-05-11 |
2011-11-17 |
Cima Labs Inc. |
Alcoholres i stant metoprolol - containing extended - release oral dosage forms
|
WO2011150300A1
(en)
|
2010-05-28 |
2011-12-01 |
Melior Pharmaceuticals I, Inc. |
Prevention of pancreatic beta cell degeneration
|
US8846723B2
(en)
|
2010-07-29 |
2014-09-30 |
Eastman Chemical Company |
Esters of O-substituted hydroxy carboxylic acids and preparations thereof
|
US20120052011A1
(en)
*
|
2010-08-24 |
2012-03-01 |
Canon Kabushiki Kaisha |
Composition and a method for producing contrast agent using the composition
|
WO2012028922A2
(en)
*
|
2010-08-30 |
2012-03-08 |
Lupin Limited |
Controlled release pharmaceutical compositions of milnacipran
|
AU2011330757B2
(en)
|
2010-11-15 |
2016-05-26 |
Neuroderm Ltd |
Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same
|
US8597683B2
(en)
|
2010-11-30 |
2013-12-03 |
Watson Pharmaceuticals, Inc. |
Modified release tranexamic acid formulation
|
EP2678320B1
(en)
|
2011-02-23 |
2018-09-19 |
Coeruleus Ltd. |
Flumazenil complexes, compositions comprising same and uses thereof
|
KR102037162B1
(ko)
*
|
2011-05-16 |
2019-10-29 |
로마크 레버러토리즈, 엘.씨. |
바이러스병, 암 및 세포내 감염으로 인한 질병의 예방 및 치료를 위한 티아졸리드 화합물의 용도
|
WO2012171015A2
(en)
*
|
2011-06-10 |
2012-12-13 |
Translational Genomics Research Institute |
Therapeutic combination for cancer treatment
|
US9561241B1
(en)
|
2011-06-28 |
2017-02-07 |
Medicis Pharmaceutical Corporation |
Gastroretentive dosage forms for minocycline
|
US9346803B2
(en)
*
|
2011-10-17 |
2016-05-24 |
Vanderbilt University |
Indomethacin analogs for the treatment of castrate-resistant prostate cancer
|
CN104105478A
(zh)
|
2011-10-28 |
2014-10-15 |
维塔利斯公司 |
抗发红组合物
|
US9717678B2
(en)
*
|
2011-11-06 |
2017-08-01 |
Murty Pharmaceuticals, Inc. |
Delivery systems for improving oral bioavailability of Fenobam, its hydrates, and salts
|
CA2859156C
(en)
*
|
2011-12-12 |
2020-10-06 |
Melior Pharmaceuticals I, Inc. |
Treatment of type i and type ii diabetes
|
US20130183263A1
(en)
|
2012-01-17 |
2013-07-18 |
Steven Hoffman |
Pharmaceutical compositions and methods
|
US10272068B2
(en)
|
2012-01-17 |
2019-04-30 |
Tyme, Inc. |
Pharmaceutical compositions and methods
|
US10646552B2
(en)
|
2012-01-17 |
2020-05-12 |
Tyme, Inc. |
Pharmaceutical compositions and methods
|
WO2013142314A1
(en)
*
|
2012-03-19 |
2013-09-26 |
Althera Life Sciences, Llc |
Oral tablet formulation consisting of immediate release rosuv astatin and extended release metformin
|
EP2836234B1
(en)
|
2012-04-12 |
2019-06-12 |
Yale University |
Vehicles for controlled delivery of different pharmaceutical agents
|
JP6175492B2
(ja)
*
|
2012-04-30 |
2017-08-02 |
カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ |
呼気中アセトン検出用センサ組成物
|
NZ703341A
(en)
|
2012-06-05 |
2016-11-25 |
Neuroderm Ltd |
Compositions comprising apomorphine and organic acids and uses thereof
|
HUE049859T2
(hu)
|
2012-06-06 |
2020-10-28 |
Nalpropion Pharmaceuticals Llc |
Készítmény magas kardiovaszkuláris kockázatnak kitett páciensekben túlsúly és elhízás kezelésére szolgáló eljárásban történõ alkalmazásra
|
RU2521572C1
(ru)
*
|
2012-12-21 |
2014-06-27 |
Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской академии наук (ИХР РАН) |
Сокристаллическая форма фенбуфена
|
WO2014122671A2
(en)
*
|
2013-02-08 |
2014-08-14 |
Hetero Research Foundation |
Solid oral compositions of saxagliptin
|
US10154971B2
(en)
|
2013-06-17 |
2018-12-18 |
Adamas Pharma, Llc |
Methods of administering amantadine
|
WO2014203140A1
(en)
|
2013-06-22 |
2014-12-24 |
Wockhardt Limited |
Solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof
|
CA2919892C
(en)
|
2013-08-12 |
2019-06-18 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded immediate release abuse deterrent pill
|
US20150118300A1
(en)
|
2013-10-31 |
2015-04-30 |
Cima Labs Inc. |
Immediate Release Abuse-Deterrent Granulated Dosage Forms
|
CN105848649B
(zh)
|
2013-11-01 |
2019-08-02 |
耶鲁大学 |
用于免疫疗法的模块化粒子
|
US9492444B2
(en)
|
2013-12-17 |
2016-11-15 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
US10172797B2
(en)
|
2013-12-17 |
2019-01-08 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
WO2015095971A1
(en)
*
|
2013-12-23 |
2015-07-02 |
Socpra Sciences Et Génie S.E.C. |
Atp synthase inhibitors and steroid alkaloids and uses thereof as antimicrobial agents and as potentiators for aminoglycosides against pathogenic bacteria
|
US10258585B2
(en)
|
2014-03-13 |
2019-04-16 |
Neuroderm, Ltd. |
DOPA decarboxylase inhibitor compositions
|
DK3116475T3
(da)
|
2014-03-13 |
2020-12-07 |
Neuroderm Ltd |
Dopa-decarboxylasehæmmersammensætninger
|
CN104208069A
(zh)
*
|
2014-05-08 |
2014-12-17 |
上海市计划生育科学研究所 |
双炔失碳酯组合物和疾病治疗方法
|
PL2959887T3
(pl)
*
|
2014-06-26 |
2019-07-31 |
Hennig Arzneimittel Gmbh&Co. Kg |
Środek leczniczy do leczenia zawrotów głowy różnego pochodzenia
|
EP3169315B1
(en)
|
2014-07-17 |
2020-06-24 |
Pharmaceutical Manufacturing Research Services, Inc. |
Immediate release abuse deterrent liquid fill dosage form
|
AU2015336065A1
(en)
|
2014-10-20 |
2017-05-04 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extended release abuse deterrent liquid fill dosage form
|
CN104523636B
(zh)
*
|
2014-12-25 |
2017-07-18 |
昆明振华制药厂有限公司 |
一种呋喃唑酮缓释片及其制备方法
|
US9925233B2
(en)
|
2015-01-30 |
2018-03-27 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9744209B2
(en)
|
2015-01-30 |
2017-08-29 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9937223B2
(en)
|
2015-01-30 |
2018-04-10 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9687526B2
(en)
|
2015-01-30 |
2017-06-27 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9750785B2
(en)
|
2015-01-30 |
2017-09-05 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9375478B1
(en)
|
2015-01-30 |
2016-06-28 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US10398662B1
(en)
|
2015-02-18 |
2019-09-03 |
Jazz Pharma Ireland Limited |
GHB formulation and method for its manufacture
|
US10722527B2
(en)
|
2015-04-10 |
2020-07-28 |
Capsugel Belgium Nv |
Abiraterone acetate lipid formulations
|
WO2017004205A1
(en)
|
2015-06-29 |
2017-01-05 |
Reveragen Biopharma, Inc. |
NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
|
KR101663543B1
(ko)
*
|
2015-07-29 |
2016-10-07 |
고려대학교 산학협력단 |
부스피론 유도체 및 이를 함유하는 약학 조성물
|
US11648212B2
(en)
*
|
2016-02-03 |
2023-05-16 |
Intelgenx Corp. |
Loxapine film oral dosage form
|
EP3484472A1
(en)
|
2016-07-14 |
2019-05-22 |
Achaogen, Inc. |
Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
|
US11602513B1
(en)
|
2016-07-22 |
2023-03-14 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
US11986451B1
(en)
|
2016-07-22 |
2024-05-21 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
US11602512B1
(en)
|
2016-07-22 |
2023-03-14 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
US11504347B1
(en)
|
2016-07-22 |
2022-11-22 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
UY37341A
(es)
|
2016-07-22 |
2017-11-30 |
Flamel Ireland Ltd |
Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
|
US10695450B2
(en)
|
2016-07-26 |
2020-06-30 |
Laboratoires Cyclopharma |
Synthesis of a radioactive agent composition
|
KR20240115925A
(ko)
|
2016-07-29 |
2024-07-26 |
얀센 파마슈티카 엔브이 |
전립선암의 치료 방법
|
WO2018064490A1
(en)
*
|
2016-09-30 |
2018-04-05 |
Xenamed Corporation |
Compositions of midodrine and methods of using the same
|
WO2018089373A2
(en)
*
|
2016-11-08 |
2018-05-17 |
Regeneron Pharmaceuticals, Inc. |
Steroids and protein-conjugates thereof
|
CN110582278B
(zh)
|
2017-03-10 |
2023-04-18 |
伊姆贝拉神经疗法公司 |
药物组合物及其用途
|
US20180263936A1
(en)
|
2017-03-17 |
2018-09-20 |
Jazz Pharmaceuticals Ireland Limited |
Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
|
CN110785170B
(zh)
|
2017-04-10 |
2023-03-28 |
梅里奥尔医药I公司 |
脂肪细胞的治疗
|
US20180318319A1
(en)
|
2017-05-04 |
2018-11-08 |
Ocular Science, Inc. |
Compositions and Methods for Treating Eyes and Methods of Preparation
|
US11478467B2
(en)
*
|
2017-05-04 |
2022-10-25 |
Sreenivasarao Vepachedu |
Targeted drug rescue with novel compositions, combinations, and methods thereof
|
WO2018213713A1
(en)
*
|
2017-05-19 |
2018-11-22 |
Embera Neurotherapeutics, Inc. |
Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease
|
WO2019014201A1
(en)
*
|
2017-07-10 |
2019-01-17 |
Apicore Us Llc |
MOLINDONE COMPOSITIONS WITH EXTENDED RELEASE
|
BR112020003375A2
(pt)
|
2017-08-24 |
2020-08-25 |
Adamas Pharma, Llc |
composições de amantadina, preparações das mesmas, e métodos de uso
|
CA3077514C
(en)
|
2017-10-25 |
2022-10-11 |
Chiesi Farmaceutici S.P.A. |
Delayed release deferiprone tablets and methods of using the same
|
EP3720435B1
(en)
|
2017-12-05 |
2024-03-06 |
Sunovion Pharmaceuticals Inc. |
Crystal forms and production methods thereof
|
WO2019113079A1
(en)
|
2017-12-05 |
2019-06-13 |
Sunovion Pharmaceuticals Inc. |
Nonracemic mixtures and uses thereof
|
JP7364568B2
(ja)
*
|
2017-12-22 |
2023-10-18 |
ゼナメッド コーポレーション |
持続放出ミドドリン塩酸塩組成物及び使用方法
|
EP3546589B1
(de)
*
|
2018-03-29 |
2022-08-10 |
Evonik Operations GmbH |
Verfahren zur herstellung von sphingolipiden
|
US10799138B2
(en)
|
2018-04-05 |
2020-10-13 |
University Of Maryland, Baltimore |
Method of administering sotalol IV/switch
|
WO2020018888A1
(en)
|
2018-07-20 |
2020-01-23 |
The Board Of Regents Of The University Of Oklahoma |
Antimicrobial peptides and methods of use
|
US11610660B1
(en)
|
2021-08-20 |
2023-03-21 |
AltaThera Pharmaceuticals LLC |
Antiarrhythmic drug dosing methods, medical devices, and systems
|
US11344518B2
(en)
|
2018-08-14 |
2022-05-31 |
AltaThera Pharmaceuticals LLC |
Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
|
US10512620B1
(en)
|
2018-08-14 |
2019-12-24 |
AltaThera Pharmaceuticals, LLC |
Method of initiating and escalating sotalol hydrochloride dosing
|
US11696902B2
(en)
|
2018-08-14 |
2023-07-11 |
AltaThera Pharmaceuticals, LLC |
Method of initiating and escalating sotalol hydrochloride dosing
|
CA3111275A1
(en)
|
2018-09-06 |
2020-03-12 |
Innopharmascreen Inc. |
Methods and compositions for treatment of asthma or parkinson's disease
|
WO2020061416A1
(en)
|
2018-09-20 |
2020-03-26 |
Levo Therapeutics, Inc. |
Carbetocin drug product and process for preparing same
|
KR20210062638A
(ko)
|
2018-09-20 |
2021-05-31 |
레보 테라퓨틱스 인코포레이티드 |
카르베토신의 안정한 비강내 제형
|
MX2021005691A
(es)
|
2018-11-19 |
2021-07-07 |
Jazz Pharmaceuticals Ireland Ltd |
Formulaciones de farmacos resistentes al alcohol.
|
KR20200077911A
(ko)
*
|
2018-12-21 |
2020-07-01 |
(주)유케이케미팜 |
잘토프로펜 함유 서방성 의약 조성물
|
US10869860B2
(en)
|
2018-12-28 |
2020-12-22 |
Vividion Therapeutics, Inc. |
Cereblon modulators and uses thereof
|
CN113473980A
(zh)
|
2019-03-01 |
2021-10-01 |
弗拉梅尔爱尔兰有限公司 |
在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
|
US11382922B2
(en)
|
2019-03-07 |
2022-07-12 |
Reveragen Biopharma, Inc. |
Aqueous oral pharmaceutical suspension compositions
|
US20220062200A1
(en)
|
2019-05-07 |
2022-03-03 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
EP3965733A4
(en)
|
2019-05-07 |
2023-01-11 |
Clexio Biosciences Ltd. |
ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE
|
US11071724B2
(en)
|
2019-05-17 |
2021-07-27 |
Ocular Science, Inc. |
Compositions and methods for treating presbyopia
|
US11160758B2
(en)
|
2019-06-04 |
2021-11-02 |
Sunovion Pharmaceuticals Inc. |
Modified release formulations and uses thereof
|
CN111000844B
(zh)
*
|
2019-12-19 |
2022-06-28 |
浙江立恩生物科技有限公司 |
一种治疗流感病毒感染的药物
|
CN110903247B
(zh)
*
|
2019-12-23 |
2022-04-05 |
常州齐晖药业有限公司 |
一种大幅降低奥芬达唑杂质b的制备方法
|
US11278602B2
(en)
|
2020-03-25 |
2022-03-22 |
Therapeutica Borealis Oy |
Medicine for Covid-19 and treatment
|
US11007187B1
(en)
*
|
2020-03-25 |
2021-05-18 |
Therapeutica Borealis Oy |
Medicine for Covid-19 and treatment
|
US11638722B2
(en)
|
2020-03-25 |
2023-05-02 |
Therapeutica Borealis Oy C/O Avance Attorneys Ltd. |
Medicine for Covid-19 and treatment
|
CN112089823B
(zh)
*
|
2020-09-25 |
2024-02-06 |
珠海中科先进技术研究院有限公司 |
一种短梗霉素a和制霉菌素组合物及其复合软膏、凝胶剂以及喷剂
|
KR20220059436A
(ko)
*
|
2020-11-02 |
2022-05-10 |
(주)아이엠디팜 |
신규한 공결정, 이를 포함하는 약학 조성물 및 이의 제조 방법
|
US11331293B1
(en)
|
2020-11-17 |
2022-05-17 |
Neuroderm, Ltd. |
Method for treatment of Parkinson's disease
|
US11213502B1
(en)
|
2020-11-17 |
2022-01-04 |
Neuroderm, Ltd. |
Method for treatment of parkinson's disease
|
US11844754B2
(en)
|
2020-11-17 |
2023-12-19 |
Neuroderm, Ltd. |
Methods for treatment of Parkinson's disease
|
CN113069421A
(zh)
*
|
2021-03-29 |
2021-07-06 |
海南锦瑞制药有限公司 |
注射用兰索拉唑
|
US11583510B1
(en)
|
2022-02-07 |
2023-02-21 |
Flamel Ireland Limited |
Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
|
US11779557B1
(en)
|
2022-02-07 |
2023-10-10 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
US12016850B2
(en)
|
2022-04-11 |
2024-06-25 |
Chiesi Farmaceutici S.P.A. |
Modified release pharmaceutical formulations comprising deferiprone
|
US12016851B2
(en)
|
2022-04-11 |
2024-06-25 |
Chiesi Farmaceutici S.P.A. |
Modified release pharmaceutical formulations comprising deferiprone
|
CN116407557A
(zh)
*
|
2023-05-29 |
2023-07-11 |
四川大学华西医院 |
一种防治出血性脑卒中的药物组合物及其应用
|
CN117607311B
(zh)
*
|
2024-01-19 |
2024-03-29 |
地奥集团成都药业股份有限公司 |
一种盐酸贝那普利对映异构体的检测方法
|